Merck & Co. saw its shares fall more than 4 percent after announcing its two experimental triplet therapies for advanced kidney cancer failed to meet their main goals in a large Phase 3 study, a significant setback for a drug combination strategy the company hoped would define the next standard of care.
"While these regimens did not demonstrate the results we hoped, the data deepen our understanding of advanced renal cell carcinoma and will help shape the next generation of treatment approaches," Dr. M. Catherine Pietanza, vice president of global clinical development at Merck Research Laboratories, said in a statement.
The LITESPARK-012 trial evaluated two three-drug regimens against the current standard, a combination of Merck’s Keytruda and Eisai’s Lenvima. The first triplet added Merck’s Welireg (belzutifan) to the mix, while the second used an investigational antibody, quavonlimab. The study, which enrolled 1,688 patients, found that neither triplet significantly improved progression-free survival or overall survival compared to the two-drug therapy alone.
The failure is a blow to Merck's strategy of building on its blockbuster immunotherapy Keytruda, whose patents begin to expire in 2028. Welireg, a newer HIF-2a inhibitor acquired in the 2019 buyout of Peloton Therapeutics, is a crucial part of the plan to offset the coming revenue loss. Analysts at Leerink Partners noted the trial's failure removes a potential $5.8 billion revenue opportunity for Welireg in the first-line setting.
Financial Fallout and Future Strategy
The disappointing results immediately impacted Merck's stock, which fell 4.08 percent to $112.34 on the day of the announcement. Welireg has been a fast-growing product for Merck, with sales surpassing $716 million in 2025, a more than 40 percent increase year-over-year. The failure in the first-line setting, however, significantly lowers the drug's peak sales projections, which consensus estimates had placed around $2.2 billion for 2030.
Despite the setback, executives from both Merck and Eisai affirmed the strength of the existing Keytruda plus Lenvima combination as the standard of care. "The findings reinforce the central role of Keytruda plus Lenvima in the first-line treatment of patients with advanced renal cell carcinoma," said Dr. Corina Dutcus, senior vice president at Eisai. Merck confirmed the results do not affect other ongoing trials in its LITESPARK program. The company is still awaiting an FDA decision, with a target date of October 4, 2026, for Welireg in combination with Lenvima for previously treated patients based on data from the LITESPARK-011 trial.
Competitive Landscape Shifts
The trial's outcome could create opportunities for competitors. Analysts at Cantor Fitzgerald noted the failure leaves a "potential first-line opening" for Arcus Biosciences' rival HIF-2a inhibitor, casdatifan. Arcus, whose shares rose 2 percent on the news, plans to start a Phase 3 trial for its drug in the first-line setting by the end of the year. Mizuho Securities analyst Salim Syed suggested the Arcus drug may be a "superior" molecule and will be tested in a different combination that may have lower toxicity.
The results underscore the high bar for improving upon the already effective Keytruda-Lenvima combination in renal cell carcinoma. For Merck, the failure highlights the challenge of developing new blockbuster therapies and the increasing importance of its existing pipeline and business development to navigate the post-Keytruda era.
This outcome narrows one of Merck's key pathways for revenue growth in the early 2030s. Investors will now be closely watching the progress of competitors like Arcus Biosciences and the results from Merck's other ongoing LITESPARK trials, particularly the LITESPARK-011 study awaiting an FDA decision.
This article is for informational purposes only and does not constitute investment advice.
